CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,400 enrolled
Drug / intervention
Shared Decision Makingbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02910089
NCT02910089Phase 4Completed

ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM): A 12-month Study of the Impact of Combined Shared-decision Making and Brief Negotiated Interviewing on Disease Control and Medication Adherence in Patients With Diabetes

AstraZeneca·interventional·Posted Sep 21, 2016·Updated Sep 17, 2019

In Brief

A Phase 4 clinical trial evaluating Shared Decision Making for Diabetes Mellitus Type 2. Completed, enrolled 1,400 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with usual care. These engagement techniques include shared decision-making and brief negotiated interviewing and are delivered telephonically.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 21, 2016
Enrollment StartOct 20, 2016
Primary CompletionDec 20, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.8 years ago

Interventions

Shared Decision Makingbehavioral

This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).